Cabio Biotech (Wuhan) Past Earnings Performance
Past criteria checks 3/6
Cabio Biotech (Wuhan)'s earnings have been declining at an average annual rate of -9.5%, while the Chemicals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 11.3% per year. Cabio Biotech (Wuhan)'s return on equity is 7.2%, and it has net margins of 22.7%.
Key information
-9.5%
Earnings growth rate
-14.6%
EPS growth rate
| Chemicals Industry Growth | 12.1% |
| Revenue growth rate | 11.3% |
| Return on equity | 7.2% |
| Net Margin | 22.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cabio Biotech (Wuhan) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 506 | 115 | 44 | 44 |
| 30 Jun 24 | 506 | 124 | 55 | 42 |
| 31 Mar 24 | 473 | 101 | 57 | 41 |
| 31 Dec 23 | 444 | 91 | 59 | 38 |
| 30 Sep 23 | 485 | 47 | 84 | 34 |
| 30 Jun 23 | 461 | 49 | 88 | 35 |
| 31 Mar 23 | 446 | 55 | 78 | 33 |
| 31 Dec 22 | 433 | 64 | 76 | 32 |
| 30 Sep 22 | 374 | 105 | 51 | 40 |
| 30 Jun 22 | 359 | 111 | 49 | 34 |
| 31 Mar 22 | 348 | 118 | 42 | 31 |
| 31 Dec 21 | 351 | 129 | 42 | 31 |
| 30 Sep 21 | 337 | 121 | 40 | 26 |
| 30 Jun 21 | 336 | 127 | 38 | 24 |
| 31 Mar 21 | 347 | 139 | 40 | 22 |
| 31 Dec 20 | 323 | 131 | 36 | 20 |
| 30 Sep 20 | 317 | 132 | 54 | 17 |
| 30 Jun 20 | 315 | 126 | 54 | 18 |
| 31 Mar 20 | 301 | 121 | 44 | 18 |
| 31 Dec 19 | 312 | 118 | 47 | 19 |
| 30 Sep 19 | 318 | 128 | 66 | 30 |
| 31 Dec 18 | 286 | 97 | 41 | 16 |
| 31 Dec 17 | 229 | 66 | 30 | 14 |
| 31 Dec 16 | 190 | 47 | 27 | 14 |
| 31 Dec 15 | 181 | 20 | 60 | 0 |
| 31 Dec 14 | 187 | 38 | 38 | 0 |
| 31 Dec 13 | 200 | 47 | 43 | 0 |
Quality Earnings: 688089 has a large one-off gain of CN¥28.2M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 688089's current net profit margins (22.7%) are higher than last year (9.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688089's earnings have declined by 9.5% per year over the past 5 years.
Accelerating Growth: 688089's earnings growth over the past year (144.8%) exceeds its 5-year average (-9.5% per year).
Earnings vs Industry: 688089 earnings growth over the past year (144.8%) exceeded the Chemicals industry -5.3%.
Return on Equity
High ROE: 688089's Return on Equity (7.2%) is considered low.